Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

uniQure N.v. QURE

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$16.1M
▼ 40.6% YoY
$-199.0M
$-178.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 16.1M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 16.1 · Net income -199.0
200M400M-150M-300M
20142017202020232025
Compound annual growth
−46.7%
−15.6%
+4.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −15.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−1236 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1151.4% · Net -1236.0%
-500%-1000%-1500%
201420192025
ROE
FY2023 · ROE -90.2%
20%40%60%-50%-100%
201420192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Gross margin89.5%
Operating margin-1151.4%
Net margin-1236.0%
EBITDAUSD -176.2M

Return on equity has no reading this year — return on capital employed, just below, still does: -29%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -178.4
100M200M-100M-200M
201420192025

Total assetsUSD 824.9M
EquityUSD 198.9M
CashUSD 80.2M
Gross debtUSD 49.7M
Net debtUSD -30.5M
Current ratio10.43×

The company holds more cash than debt.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
QURE, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.10.50.00.00.00.00.00.00.0
Operating income $B−0.2−0.2−0.3−0.10.3−0.1−0.1−0.1−0.1−0.1−0.1−0.1
EBITDA $B−0.2−0.2−0.3−0.10.3−0.1−0.1−0.1−0.1−0.1−0.1−0.1
Income tax $B0.00.00.0−0.00.0−0.0◌0.0−0.00.0−0.0−0.0
Net income $B−0.2−0.2−0.3−0.10.3−0.1−0.1−0.1−0.1−0.1−0.1−0.0
Free cash flow $B−0.2−0.2−0.2−0.20.3−0.1−0.1−0.1−0.1−0.1−0.0−0.1
EPS, diluted $−3.46−4.92−6.47−2.717.04−2.81−3.11−2340.00−2940.00−2.93−3.72−2.91
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %——−90.2−23.778.5−44.1−49.4−61.9−103.6−76.6−96.3−116.8
Shares out B0.060.050.050.050.050.040.040.040.030.030.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Nine checks were skipped: cost of revenue is not tagged before 2016. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image